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Introduction 
 
Guar gum (GG), also known as guar flour, is a non-
ionic polysaccharide gum, obtained from the ground 
endosperm of the seed of the leguminous guar plant, 
Cyamopsis tetragonoloba (Sahoo et al. 2013). It is an 
almost odourless and tasteless powder, with a whitish 
yellow colour. The guar beans have an endosperm con-
taining a galactomannan gum (Saikh and Kumar, 
2011), made of high molecular weight polysaccharides 
(Sahoo et al. 2013). The guar powder is insoluble in 
organic solvents, but forms a gel-like consistency in 
water (Sahoo et al. 2013). The GG polysaccharide 
comprises 80% galactomannan, being made of (1→4)-
β-D mannopyranosyl (mannose) linear chains attached 
to units of α-D-galactopyranose, by (1→6) glycosidic 
linkages (Hartemink et al. 1999, Sahoo et al. 2013). 
Mannose and galactose are usually present in a ratio of 
2:1 (Hartemink et al. 1999, Sahoo et al. 2013, Saikh & 
Kumar 2011). GG is used in various fields, like in the 
food industry (Hartemink et al. 1999, Sahoo et al. 
2013), and in the pharmaceutical industry (Saikh & 
Kumar 2011). Guar gum has been used as a drug deliv-
ery system in the form of tablets and capsules, allow-
ing for the slow release of the drug (Sahoo et al. 2013).  
 In recent years, a wide variety of different 
nanoparticles have been synthesized with different sur-
face chemical properties. The guar gum nanoparticle 
(GN), used in this study, has been designed for uptake 
in cell systems (Ghosh et al. 2015). The GN, prepared 
by acid hydrolysis of GG, has been extracted without 
the use of any organic solvent, modified covalently 
and then made to undergo an epichlorohydrin reaction 
in liquid ammonia (Ghosh et al. 2015). The resultant 
GN molecule was spherical in shape and has a size of 
about 80 nm, with a mannose: galactose ratio of 4:1. 
The GN molecules were further covalently functional-
ized in aqueous environment with rhodamine isothio-
cyanate (RITC) using a hydroxypropyl amine spacer 
group, for potential applications in bioimaging (Ghosh 
et al. 2015). 
 The ability to be taken up by cells depend 
upon the nanoparticle’s size, its surface-to-charge ra-
tio, and its ability to bind to cell membranes. Nanopar-
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The potential to deliver nanoparticles, like polymer-
based nanoparticles that can be enriched with func-
tional groups to ensure entry into cells, directly into 
targeted cells is important for the therapy of inflamma-
tory diseases. Plant-derived nanoparticles, with inher-
ent anti-inflammatory activity and modified to allow 
receptor-mediated uptake, can be used as effective 
therapy with minimal side effects. The particle used in 
this study is an edible polysaccharide, derived from 
Cyamopsis tetragonoloba, with a galactomannan com-
ponent. The particle was made mannose-rich to in-
crease specificity towards cells expressing mannose 
receptors, and initially tagged with rhodamine isothio-
cyanate to trace its path. This study aimed to determine 
the therapeutic effect of the guar gum nanoparticle 
(GN) in vitro and in vivo in inflammatory diseases. In 
vitro studies on RAW 264.7 cells showed successful 
uptake of the nanoparticle, in a short duration of time, 
via their mannose receptors. Nitric oxide and MTS 
assays showed anti-inflammatory effects of GN. In 
vivo mouse model of thioglycollate-induced peritonitis 
showed significant decrease in inflammation, indicat-
ing its anti-inflammatory effect, and increase in clono-
genic potential, indicating its regenerative potential, on 
intraperitoneal administration of GN. The results re-
flect the potential of the nanoparticle in cellular traf-
ficking, site- specific drug delivery and bioimaging 
applications.  
Abstract 
ticles show high affinity for cell membranes due to 
electrostatic interactions, which are mainly decided by 
the zeta potential of the nanoparticles (Honery & Zahir 
2013). 
 Macrophages, which have mannose receptors 
on their surfaces, play a critical role in the innate and 
adaptive immune responses. The mannose rich GN 
was used in this study to check its uptake via mannose 
receptors expressed on different cells, like macro-
phages. The mannose receptor (MR), a C-type lectin 
that helps in internalization of endogenous, as well as 
exogenous microbe-derived, substances, recognizes 
carbohydrate molecules by its cysteine-rich domains 
(Leteux et al. 2000, Liu et al. 2000, McKenzie et al. 
2007). Macrophages also express galactose receptors. 
Macrophage galactose binding lectin (MGL) is also a 
C-type lectin on macrophages, which bind to galactose 
and related sugars (Kawasaki et al. 1986, Suzuki et al. 
1996) and is a very efficient receptor for internaliza-
tion (Higashi et al. 2002). 
 Peritonitis is the inflammation of the perito-
neum, the thin covering that lines the inner wall of the 
abdomen, covering the organs present in the abdomi-
nal cavity (Mitra et al. 2015). Peritonitis is caused by 
disruptions of the peritoneum or due to some systemic 
infection (Mitra et al. 2015). Peritonitis, induced in 
mice using thioglycollate (TG) leads to an increase in 
peritoneal macrophages within 24 hours of infection 
(Lam et al. 2013, Zhang et al. 2008). 
 The objective of this work can be divided into 
two main parts: the in vitro studies on murine macro-
phage cell lines and the in vivo studies in a mouse 
model of an inflammatory disease, i.e. aseptic peritoni-
tis. The in vitro studies were done to determine the 
time over which GN was taken up by the cells, to as-
sess whether the GN was taken up by the cells via their 
mannose receptors, and to assess whether GN has any 
anti-inflammatory and/ or proliferative effect on the 
cells. The in vivo studies were done to assess the anti-
inflammatory effects of GN in TG induced peritonitis, 
where the involvement of macrophages, containing 
mannose receptors, has been documented.  
 
Materials and Methods 
 
Guar gum nanoparticle (GN) 
Guar gum nanoparticle was obtained from the labora-
tory of Dr. Arup Mukherjee, Department of Chemical 
Technology, University of Calcutta, Kolkata, India 
where it was prepared by using the protocols previ-
ously published (Ghosh et al. 2015). The GN was 
tagged with RITC (absorption maxima: 560 nm; emis-
sion maxima: 580 nm) for the in vitro and ex vivo up-
take studies. Untagged GN was used for the in vivo 
studies. 
 
In vitro experiments 
 
Cell Culture 
RAW 264.7 macrophage cells were cultured in our 
laboratory (Immunology & Regenerative Medicine 
Research Laboratory, Department of Zoology, Univer-
sity of Calcutta, Kolkata, India). The cells were grown 
in DMEM (Himedia, India), supplemented with 10% 
FBS (Himedia, India) and 1% Pen-Strep (Himedia, 
India), and incubated at 37°C with 5% CO2 in a CO2 
incubator (Thermo Fisher Scientific BB15). When the 
cells reached 80% confluency, they were passaged into 
6-well plates and 96-well plates for further assays. 
 
Cellular uptake and cell viability for GN (RITC tagged 
guar nano) 
a) In vitro treatment of RAW 264.7 cells with GN (for 
30 min and 60 min) 
1×104 RAW 264.7 cells were seeded on gelatin coated 
coverslips, and allowed to adhere and grow till 70% 
confluent. The adhered cells were treated with 40 µg/
ml RITC-tagged GN for 30 min and 60 min, at 37°C 
with 5% CO2. The cells were washed with 1X PBS 
(Himedia, India), fixed with 4% paraformaldehyde 
(TCI, Japan) for 20 minutes, washed and counter-
stained with 300 nM DAPI (Invitrogen, USA). The 
coverslips were mounted on clean slides and visualized 
under Andor spinning disk confocal microscope, under 
the specific set of filters. 
 
b) In vitro inhibitory studies for the mannose receptor 
mediated uptake in RAW 264.7 cells 
Since GN is a galactose-mannose rich compound, to 
assess whether they are taken up by the macrophages 
via their mannose receptors or their galactose recep-
tors, a receptor-inhibition study was carried out. 1x104 
RAW 264.7 cells were seeded on gelatin coated cover-
slips, and allowed to adhere and grow till 70% conflu-
ent. The adhered cells were treated with 5mM Galac-
tose (Himedia, India), 1mM Mannose (Himedia, India) 
and 5mM Mannose (Himedia, India) in separate sets 
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 Time 
Total no. of 
cells 
GN
+
 cells 
Percentage GN 
uptake 
30 min 37.0 ± 5.0 26.0 ± 6.0 70.3% 
60 min 33.0 ± 3.5 32.0 ± 3.5 96.9% 
Table 1. Percentage uptake of GN by RAW 264.7 cells 
with time. RAW 264.7 cells were incubated with GN for 30  
and 60 mins. Uptake increased from 70.3% in 30 mins to 
96.9% in 60 mins.   
and incubated for 30 mins. Then, they were treated 
with 40 µg/ml RITC-tagged GN and incubated at 37°C 
with 5% CO2 for 1 hr. The cells were washed with 1X 
PBS (Himedia, India), fixed with 4% paraformalde-
hyde (TCI, Japan) for 20 minutes, washed and counter-
stained with 300 nM DAPI (Invitrogen, USA). The 
coverslips were mounted on clean slides and visualized 
under Andor spinning disk confocal microscope, under 
the specific set of filters. 
 
In vitro anti- inflammatory effect of GN Nitric oxide 
(NO) Assay 
1× 104 RAW 264.7 cells were seeded per well into the 
wells of a 96-well plate (Nest Biotech, China) in tripli-
cate and incubated for 24 hrs at 37°C with 5% CO2. 
One group of cells was treated with 1 µg/ml LPS 
(Sigma Aldrich) for 2 hrs and the other group without 
LPS. The cells were then treated with 40 µg/ml GN in 
respective wells for 1 hr at 37°C with 5% CO2. 50 µl 
of 1% Sulfanilamide (SRL, India) in 5% o-phosphoric 
acid (Merck, India) was added to the wells and incu-
bated at room temperature for 5 minutes in the dark. 50 
µl of 0.1% NED [N-1-napthylethylenediamine dihy-
drochloride (SRL, India)] solution was added to the 
wells, and incubated at room temperature for 5 minutes 
in the dark. Absorbance was measured at 540 nm and 
concentration of NO in the samples was determined 
from a standard curve.   
 
MTS Assay 
1× 104 RAW 264.7 cells were seeded per well into the 
wells of a 96-well plate (Nest Biotech, China) in tripli-
cate and incubated for 24 hrs at 37°C with 5% CO2. 
One group of cells was treated with 1 µg/ml LPS 
(Sigma Aldrich) for 2 hrs and the other group without 
LPS. The cells were then treated with 40µg/ml GN in 
respective wells and incubated at 37°C with 5% CO2 
for 1 hr. Cell proliferation was assessed using the 
Promega CellTiter 96® AQueous Non-Radioactive 
Cell Proliferation Assay Kit, where 1000µl of MTS 
reagent was mixed with 50 µl of PMS reagent. 20 µl of 
this mixture was added to each well, and incubated at 
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Figure 1. Time dependent uptake of GN by RAW 264.7 cells. RAW 264.7 cells were incubated with GN for (I) 30 mins and 
(II) 60 mins, counterstained with DAPI and observed under the Andor spinning disk confocal microscope. About 70% of all 
the cells took up the GN in 30 minutes, while over 96% of all the cells took up the GN in 60 mins. A: Cells stained with GN; 
B: Cells counterstained with DAPI; C: Merged image. (III) Graphical representation of the number of cells that have taken up 
GN with time (in 30 and 60 mins) as compared to the total number of cells. 
Treatments 
High intensity of GN Low intensity of GN 
No. of cells 
Percentage of total 
cells 
No. of cells 
Percentage of total 
cells 
5mM Galactose 9.5 ± 0.5 79.17% 2.5 ± 0.5 20.83% 
1mM Mannose 3.5 ± 0.5 38.89% 5.5 ± 1.5 61.11% 
5mM Mannose 3.5 ± 2.5 26.92% 9.5 ± 7.5 73.08% 
Table 2. Uptake of GN in presence of 5 mM Galactose, 1 mM Mannose and 5 mM Mannose. Galactose was not able to inhibit 
the uptake of GN as much as mannose. 5 mM mannose was a better inhibitor than 1 mM mannose. 
37°C with 5% CO2 for 3 hours. Absorbance was meas-
ured at 490 nm. Considering the proliferation of the 
untreated cells to be 100%, the corresponding prolif-
eration of the other groups was calculated.  
 
Ex vivo experiments 
 
Uptake of GN by primary culture of peripheral blood 
cells  
After testing the uptake of GN in RAW macrophage 
cell lines, we wanted to test whether it is also taken up 
by other cell types. For this, we treated adherent blood 
cells with GN and immunostained with fluorescent-
tagged CD45 (marker for hematopoietic lymphocytes). 
104 peripheral blood cells from a BALB/c mouse were 
seeded on 0.2% gelatin-coated coverslips and incu-
bated at 37°C with 5% CO2. The adherent cells were 
checked routinely. After the cells reached 70-80% con-
fluence, they were treated with 40 µg/ml RITC-tagged 
GN in dark and incubated for 2 hrs at 37°C with 5% 
CO2 under humidified atmosphere. The adhered cells 
were washed with 1X PBS (Himedia, India) thrice for 
10 minutes and fixed with 4% paraformaldehyde (TCI, 
Japan) for 20 minutes at room temperature. The cells 
were washed thrice with 1X PBS for 10 minutes and 
blocked with 2% BSA (Biosera) in PBS (blocking 
buffer) for 1 hr at room temperature. 1:100 CD45-
PerCP/Cy5.5, diluted in blocking buffer, was added to 
the cells overnight at 4°C. The cells were rinsed thrice 
with blocking buffer for 10 minutes away from light, 
and then counterstained with 300 nm DAPI 
(Invitrogen, USA) for 15 minutes. The coverslips were 
mounted on clean slides and visualized under Andor 
spinning disk confocal microscope, under the specific 
set of filters. 
 
In vivo experiments 
 
Animals  
BALB/c mice (7–9 weeks old, 20–22 g) were pur-
chased from National Institute of Nutrition (NIN), Hy-
derabad, India. They were housed under specific 
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Figure 2. Effect of inhibitory molecules on the uptake of GN by RAW 264.7 cells. RAW 264.7 cells were pre-incubated with 
(I) 5 mM Galactose, (II) 1 mM Mannose and (III) 5 mM Mannose for 30 mins, followed by GN for 60 mins, counterstained 
with DAPI and observed under the Andor spinning disk confocal microscope. In (I), many cells showed a high intensity of GN, 
while few showed low intensity, indicating that there was very little inhibition of GN-uptake by galactose. In (II), few cells 
showed a high intensity of GN, while many showed low intensity, indicating that there was some inhibition of GN-uptake by 
mannose. In (III), few cells showed a high intensity of GN, while most of the cells showed low intensity, indicating that 5 mM 
mannose was better at inhibiting the GN-uptake as compared to both 5 mM galactose and 1 mM mannose. A: Cells stained 
with GN; B: Cells counterstained with DAPI; C: Merged image. (IV) Graphical representation of the effect of pre-incubation 
with inhibitory molecules (galactose and mannose) on the uptake of GN by RAW 264.7 cells. 
pathogen free conditions at the animal house of the 
Department of Zoology, University of Calcutta, and 
given sterilized water and standard mouse food under 
12 hour light and dark cycle throughout the study, ac-
cording to the rules set by the Institutional & Depart-
mental Ethics Committees. All experiments were per-
formed according to rules laid down by the Institu-
tional and departmental animal ethics committee. 
The mice were divided into three groups,  
a) Control group: Mice were untreated (n=2). 
b) TG group: Mice were treated intraperitoneally with 
3% thioglycollate for 24 hours (n=2). 
c) TG+GN group: Mice were treated intraperitoneally 
with 3% thioglycollate, followed by an intraperitoneal 
treatment of 200 µg GN (n=2). 
 
Treatment of mice 
In vivo experiments were done in a mouse model of 
peritonitis. Peritonitis was induced by intraperitoneal 
treatment with thioglycollate, which leads to onset of 
disease within 24 hours, and continues till at least 96 
hours. The mice in the TG groups were treated with 
200 µl of 3% TG (Himedia, India), dissolved in 1X 
PBS (Himedia, India) intraperitoneally on Day 0. Mice 
in the TG+GN group were treated intraperitoneally 
with 200 µg GN 1 hour after intraperitoneal treatment 
with 3% TG. The mice were sacrificed 24 hours after 
treatment by cervical dislocation, and peritoneal fluid 
and peripheral blood were collected. The peritoneal 
fluid was collected injecting 1ml 1X PBS, for dislodg-
ing the attached cells in the peritoneum. The peripheral 
blood was collected through cardiac puncture.  
 
 
Total Cell (TC) Count 
The total count and viability of cells in the peripheral 
blood and peritoneal fluid was checked by Trypan blue 
staining. Equal volumes of cell suspension and trypan 
blue (Himedia, India) were mixed and loaded into a 
haemocytometer, and counted under the microscope. 
The TC (number of cells/ ml) was plotted.     
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Table 3. NO and MTS assay of RAW 264.7 cells in presence of LPS and GN. The NO concentration increased by 1.46 fold 
(p<0.05) with GN alone, by 1.78 fold (p<0.05) with LPS alone, and decreased by 1.07 fold with LPS and GN. Cell prolifera-
tion increased by 1.22 fold with GN alone, decreased by 1.12 fold (p<0.05) with LPS alone, and increased by 1.28 fold 
(p<0.05) with LPS and GN. 
Treatments 
NO Assay MTS Assay 
Concentration 
of NO (µM) 
Fold change, with 
respect to Absorbance 
(540 nm) 
Proliferation 
(%) 
Fold change, with 
respect to 
RAW - 
LPS 
RAW 
+ LPS 
RAW-
LPS 
RAW+ 
LPS 
RAW 2.90 ± 0.09   0.665 ± 0.097 100   
RAW+LPS 5.17 ± 0.52 (+) 1.78*  0.595 ± 0.027 89.47 (-) 1.12  
RAW+LPS+
GN 
4.85 ± 7.30 (+) 1.67 (-) 1.07 0.759 ± 0.022 114.09 (+) 1.14 (+) 1.28* 
Figure 3. In vitro anti-inflammatory effects of GN on LPS- induced RAW 264.7 cells. Effect of treatment with GN on the (A) 
nitric oxide production by, and (B) on the proliferation of, LPS-induced RAW 264.7 cells. GN showed a 1.07 fold decrease in 
the NO content, and a 1.28 fold increase (p<0.05) in the proliferation. (*: p<0.05, with respect to untreated RAW 264.7; #: 
p<0.05, with respect to RAW 264.7 treated with LPS). 
Differential Cell (DC) Count 
Smears were prepared on microscope slides with pe-
ripheral blood and peritoneal fluid. The smears were 
fixed with methanol, and stained using Giemsa stain 
(Merck, India) for 15 minutes. The number of mono-
cytes and neutrophils were counted under 40X magni-
fication of a light microscope (Dewinter, India), and 
the DC (in %) of each cell type was plotted.   
 
CFU assay 
For quantification of the clonogenic potential (ability 
of cells to form colonies), the colony forming unit 
(CFU) assay was performed in a semi-solid medium 
using standard protocol. The methyl cellulose semi-
solid medium was prepared using IMDM (Himedia, 
India), FBS (Himedia, India), Pen-Strep (Himedia, 
India), BSA (Biosera, USA), murine stem cell factor 
(BioVision, USA) and methyl cellulose (Himedia, In-
dia). 500 µl medium was dispensed into the wells of a 
24-well plate. Blood and peritoneal fluid cell suspen-
sions were prepared by filtering the cells through a 
nylon mesh in separate tubes. 500 µl of the prepared 
cell suspension was then added to the medium in the 
plate, and incubated at 37°C with 5% CO2 in a humidi-
fied chamber for 7-14 days. The total numbers of colo-
nies were then counted using FLoid Cell Imaging Sta-
tion (Thermo Fisher Scientific) under 20X magnifica-
tion, and the clonogenic potential was calculated by 
dividing the total number of colonies obtained by the 
number of cells plated.   
MTT assay 
100 µl of 106 cells of peritoneal fluid were plated in 
the wells (105 cells per well) of a 96- well plate and 
incubated overnight at 37°C with 5% CO2 in a humidi-
fied chamber. The cells were treated with 5µl of 0.5 
mg/ml MTT (SRL, India) in 1X PBS, and incubated at 
37°C with 5% CO2 in a humidified chamber for 3 
hours. The media was discarded and 150 µl of acidi-
fied isopropanol [0.04 M HCl (Merck, India) in isopro-
panol (SRL, India)] was added to each well and incu-
bated at 37°C with 5% CO2 in a humidified chamber 
for 30 minutes. The absorbance was measured at 540 
nm. Considering the proliferation of the cells of the 
untreated control group to be 100%, the corresponding 
proliferation of the other groups was calculated. 
 
NO assay 
50 µl of 106 cells of peripheral blood and peritoneal 
fluid were plated in the wells (0.5 x 105 cells per well) 
of a 96-well plate and incubated overnight at 37°C 
with 5% CO2 in a humidified chamber. 50 µl of 1% 
sulphanilamide (SRL, India) in 5% o-phosphoric acid 
(Merck, India) was added to the wells for 5 minutes at 
room temperature in the dark. 50 µl of NED (SRL, 
India) was added for 5 minutes at room temperature in 
the dark. Absorbance was measured at 540 nm. The 
concentration of nitric oxide released by the cells was 
calculated from a standard curve.  
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Treatments 
Peripheral blood (PB) Peritoneal fluid (PF) 
TC (x 108/ml) 
Fold change, with re-
spect to TC (x 106/ml) 
Fold change, with respect 
to 
Control TG Control TG 
Control 2.68 ± 0.38   4.37 ± 0.77   
TG 3.44 ± 1.40 (+) 1.29  8.17 ± 0.07 (+) 1.87*  
TG+GN 2.69 ± 0.99  (-) 1.28 5.40 ± 0.44  (-) 1.51* 
Table 4. Total cell count of PB and PF of untreated mice and mice treated with TG and GN. Treatment with TG caused a 1.29 
fold increase in TC of PB, while GN caused a 1.28 fold decrease. Treatment with TG caused a 1.87 fold increase (p<0.05) in 
TC of PF, while GN caused a 1.51 fold decrease (p<0.05). 
Figure 4. Uptake of GN by primary cells. Peripheral blood 
cells were incubated with GN for 2 hrs, stained with CD45-
PerCP/Cy5.5, counterstained with DAPI and observed un-
der the Andor spinning disk confocal microscope. Almost 
100% of the total number of CD45+ and DAPI+ cells took 
up the GN in 2 hrs. A: Cells stained with GN; B: Cells 
stained with CD45-PerCP/Cy5.5; C: Cells counterstained 
with DAPI; D: Merged image. 
Flow Cytometry 
Peripheral blood was collected in 1X RBC lysis buffer 
(Himedia, India), kept at room temperature for 5 min-
utes, 1X PBS added and centrifuged at 2000 rpm for 5 
minutes at 4˚C. The pellet was washed again with 1X 
PBS (centrifuged at 2000 rpm for 5 minutes at 4˚C). 
Similarly, peritoneal fluid cells were washed with 1X 
PBS. The pellets were then stained with two combina-
tions of antibodies: a) 1:50 CD 45- PerCP-Cy5.5 
(BioLegend, USA) together with 1:50 CD3- PE (BD 
Biosciences, India) + 1:50 B220- FITC (BD Biosci-
ences, India) and b) 1:50 CD 45- PerCP-Cy5.5 
(BioLegend, USA) together with 1:50 F4/80- PE 
(Invitrogen, USA) + 1:50 GR1- FITC (MACS 
Miltenyi Biotec). The pellets were stained for 20 min-
utes in the dark, centrifuged at 2000 rpm for 5 minutes 
at 4˚C, and the pellet resuspended in 1X PBS. Flow 
cytometry was done using FACSVerse (BD Biosci-
ences, USA), where 20000 CD45+ events were gated 
out from the total events and counted. The flow cy-
tometry results were analysed using the FACSuite soft-
ware (BD Biosciences, USA). 
 
Statistical Analysis 
All data have been presented as Mean ± SEM. Statisti-
cal significance has been calculated using t-test, con-
sidering all values of p<0.05 to be significant. All data 
have been analysed, and graphs have been prepared, 
using GraphPad Prism 6 software.  
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Treatments 
Neutrophils Monocytes 
DC (%) 
Fold change, with re-
spect to DC (%) 
Fold change, with 
respect to 
Control TG Control TG 
PB- Control 4.67 ± 0.47   8.49 ± 1.77   
PB- TG 8.70 ± 0.13 (+) 1.86*  9.39 ± 2.04 (+) 1.11  
PB- TG+GN 8.23 ± 0.79  (-) 1.06 7.41 ± 0.03  (-) 1.27 
PF- Control 2.17 ± 1.07   8.69 ± 1.00   
PF- TG 7.33 ± 0.88 (+) 3.38  13.02 ± 1.73 (+) 1.50  
PF- TG+GN 5.23 ± 0.10  (-) 1.40 4.57 ± 0.57  (-) 2.85* 
Figure 5. Effect of GN on infiltration and 
function of peripheral blood cells. Effect of 
TG and GN on the total cell count of pe-
ripheral blood cells (A), as determined us-
ing Trypan blue and counted using a 
haemocytometer, on the differential cell 
count of neutrophils (B) and monocytes (C) 
in blood, as determined by Giemsa stain-
ing, and observed under 40X magnifica-
tion, and on the concentration of nitric ox-
ide released by peripheral blood cells (D), 
as determined by NO assay at 540 nm. (*: 
p<0.05, with respect to untreated control).  
Table 5. Differential cell count of PB and PF of untreated mice and mice treated with TG and GN. Treatment with TG caused 
a 1.86 fold increase (p<0.05) in neutrophils and a 1.11 fold increase in monocytes of PB; 3.38 fold increase in neutrophils and 
a 1.50 fold increase in monocytes of PF. GN caused a 1.06 fold decrease in neutrophils and a 1.27 fold decrease in monocytes 
of PB; 1.40 fold decrease in neutrophils and a 2.85 fold decrease (p<0.05) in monocytes of PF. 
Results 
 
In vitro 
 
Time dependent uptake studies for GN with RAW 264.7 
cells 
RAW 264.7 cells, incubated for 30 minutes with GN, 
showed a 70% uptake of GN (Figure 1-I). This uptake 
was increased to 96% when the incubation time was 
increased to 60 minutes (Figure. 1-II). The uptake was 
calculated by counting all the DAPI-positive cells 
which represented the total number of cells and the 
RITC-positive cells, observed under the Andor spin-
ning disk confocal microscopy. The number of RITC-
positive cells among the total DAPI-positive cells gave 
the percentage of GN uptake (Table 1 and Figure 1-
III).  
 
Effect of inhibitory molecules on the uptake of GN 
Macrophage cells express mannose receptors, as well 
as some galactose receptors, on their surface. In order 
to determine whether the GN was taken up by the 
macrophages via their mannose or galactose receptors 
(since GN is a galactose- mannose rich molecule), in-
hibitory experiments were conducted in which the cells 
were pre-treated with the free mannose and free galac-
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Figure 6. Effect of GN on infiltration and function of peritoneal fluid cells. Effect of TG and GN on the total cell count of peri-
toneal fluid cells (A), as determined using Trypan blue and counted using a haemocytometer, on the differential cell count of 
neutrophils (B) and monocytes (C) in PF, as determined by Giemsa staining, and observed under 40X magnification, on the 
clonogenic potential of PF cells (D) as determined by the CFU assay, on the proliferation of PF cells (E), as determined by the 
MTT assay at 540 nm, and on the concentration of nitric oxide released by peripheral blood cells (F), as determined by NO 
assay at 540 nm. (*: p<0.05, with respect to untreated control; #: p<0.05, with respect to TG- treated).  
Treatments 
Peripheral blood (PB) Peritoneal fluid (PF) 
Concentration 
(µM) 
Fold change, with 
respect to Concentration 
(µM) 
Fold change, with re-
spect to 
Control TG Control TG 
Control 3.64 ± 1.95   5.09 ± 0.60   
TG 9.84 ± 0.45 (+) 2.70  8.24 ± 0.15 (+) 1.62*  
TG+GN 8.24 ± 0.35  (-) 1.19 5.34 ± 0.45  (-) 1.54* 
Table 6. NO assay of PB and PF of untreated mice and mice treated with TG & GN. Treatment with TG caused a 2.70 fold 
increase in the concentration of nitric oxide in PB, while GN caused a 1.79 fold decrease. Treatment with TG caused a 1.62 
fold increase (p<0.05) in the concentration of nitric oxide in PF, while GN caused a 1.54 fold decrease (p<0.05). 
tose before adding GN. The free sugars were rapidly 
taken up by the cells, thus preventing the galactose-
mannose rich GN from entering the cell. Thus the fluo-
rescence of the particles (RITC-positive cells) among 
the total number of cells (DAPI-positive cells) was 
measured on the basis of intensity. Cells with low in-
tensity of GN showed some inhibition, whereas the 
cells with high intensity of GN did not show inhibi-
tion. In presence of 5 mM galactose, 79% of cells 
showed high intensity, while only 20% of the cells 
showed inhibition (Figure 2-I). Uptake was inhibited 
by 61% in presence of 1 mM mannose (Figure 2-II) 
and by 73% in presence of 5 mM mannose (Figure 2-
III). Thus 5 mM mannose was effectively blocking the 
uptake of the mannose rich GN (Table 2 and Figure 2-
IV). This may indicate that the GN was indeed taken 
up by the cells via the mannose receptors, but not via 
the galactose receptors.  
 
NO Assay and MTS Assay of RAW 264.7 cells 
Generally, inflammation leads to an increase in the 
nitric oxide released by cells. To induce an inflamma-
tory condition, RAW 264.7 cells were treated with 
LPS. The cells showed a 1.78 fold increase (p<0.05) in 
the NO concentration on treating with LPS as com-
pared to untreated control. In presence of LPS, the 
cells treated with GN (RAW+LPS+GN) showed a 1.07 
fold decrease with respect to the LPS treated cells 
(RAW+LPS) (Table 3 and Figure 3A). After checking 
the inflammatory condition, MTS assay was done to 
estimate the proliferative capacity of cells. In inflam-
matory conditions, the proliferation of cells reduces, to 
be restored by therapy. RAW 264.7 cells, on treating 
with LPS, showed a 1.12 fold decrease in cell prolif-
eration with respect to untreated control. In presence of 
LPS, the cells treated with GN (RAW+LPS+GN) 
showed a 1.28 fold increase (p<0.05) with respect to 
the LPS treated cells (RAW+LPS) (Table 3 and Figure 
3B). 
 
 
In vivo 
 
Effect of TG and GN on peripheral blood 
At the first stages of inflammation, the body tries to 
counter the inflammatory attack by its innate immune 
system. This leads to an influx of cells to the site of 
inflammation, in this case, the peritoneum. Since the 
cellular infiltration into the peritoneum occurs via the 
blood, the number of cells in the peripheral blood also 
increases. This increase in cells can be assessed by the 
total cell (TC) count. On treatment with TG, the TC of 
the peripheral blood (PB) was found to have increased. 
There was a 1.29 fold increase in the TC of PB of TG-
treated group, as compared to the TC of the untreated 
control. Increase in the TC indicates development of 
the inflammation. GN treatment successfully reduced 
the cellular infiltration by 1.28 fold in the PB as com-
pared to the TC of TG- treated mice (Table 4 and Fig-
ure 4A). The differential count of neutrophils in the PB 
of mice treated with TG showed a 1.86 fold increase 
(p<0.05), and monocytes showed a 1.11 fold increase, 
compared to control. Treatment with GN led to a de-
crease of 1.06 fold in the neutrophils and a decrease of 
1.27 fold in monocytes (Table 5, Figure 4B and 4C), 
compared to TG- treatment. Nitric oxide released by 
peripheral blood cells on treatment with TG increased 
2.70 fold, and was reduced by 1.19 fold (p<0.05) after 
treatment with GN (Table 6 and Figure 4D). The pe-
ripheral blood cells, adhered on gelatin-coated cover-
slips, also took up GN. Most of the adherent blood 
cells were CD45+ (hematopoietic lymphocytes). 
Among these CD45+ cells, almost 100% were also 
GN+ (Figure 5). This indicated that GN was taken up 
non-specifically by all types of lymphocytes, thereby 
limiting any potential use as an in vivo cellular tag.   
 
Effect of TG and GN on peritoneal fluid 
The influx of cells into the inflammatory site in the 
peritoneum was increased due to inflammatory re-
sponse which occurred after administering TG. There 
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Treatments 
Clonogenic  
Potential  
(x 10-5) 
Fold change, with 
respect to 
Control TG 
Control 0.64 ± 0.25   
TG 0.09 ± 0.02 (-) 7.11  
TG+GN 0.43 ± 0.05  (+) 4.78* 
Treat-
ments 
Absorb-
ance 
(540 nm) 
Prolifera-
tion 
 (%) 
Fold change, with 
respect to 
 Control TG 
Control 
0.039 ± 
0.011 
100.00    
TG 
0.031 ± 
0.007 
78.21 (-) 1.28   
TG+GN 
0.035 ± 
0.018 
88.46   (+) 1.13 
Table 7. CFU assay of peritoneal fluid of untreated mice 
and mice treated with TG and GN. Treatment with TG 
caused a 7.11 fold decrease in the clonogenic potential, 
while GN caused a 4.78 fold increase (p<0.05). 
Table 8. MTT assay of peritoneal fluid of untreated mice 
and mice treated with TG and GN. Treatment with TG 
caused a 1.28 fold decrease in the cell proliferation, while 
GN caused a 1.13 fold increase. 
was a 1.87 fold (p<0.05) increase in the TC of perito-
neal fluid (PF) of TG- treated group, as compared to 
the TC of the untreated control. GN treatment success-
fully reduced the cellular infiltration by 1.51 fold 
(p<0.05) in the PF, compared the TC of TG-treated 
mice (Table 4 and Figure 6A). In the PF, there was a 
3.38 fold increase in neutrophils, and a 1.50 fold in-
crease in monocytes, with TG treatment compared to 
control. GN treatment was successful in reducing the 
neutrophils by 1.40 fold and monocytes by 2.85 fold 
(p<0.05), versus the TG-treated mice (Table 5, Figure 
6B and 6C). In the peritoneal fluid, the NO concentra-
tion increased by 1.62 fold (p<0.05) with TG, in com-
parison to untreated control. NO concentration showed 
a significant, 1.54 fold (p<0.05) decrease with GN 
treatment, versus TG treatment (Table 6 and Figure 
6F).Since the clonogenic potential is the ability of cells 
to form colonies, it is an indication of the regenerative 
potential of a therapeutic molecule. In inflammation, 
the clonogenic potential is found to reduce as com-
pared to untreated cells. A good therapeutic molecule 
will be able to restore the clonogenic potential of the 
diseased cells. Treatment with TG showed a 7.11 fold 
decrease in the clonogenic potential of PF cells as 
compared to untreated control. GN successfully re-
stored the clonogenic potential compared to TG-
treatment, with a 4.78 fold (p<0.05) increase (Table 7 
and Figure 6D). MTT assay indicates the proliferative 
capacity of the cells. Proliferation of the PF cells of 
untreated control, TG-treated and TG+GN-treated cells 
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Figure 7. Flow cytometric analysis of peripheral blood done using BD FACSVerse. (I) 20,000 events were counted from gated 
CD45+ cells (UL: Upper left quadrant; UR: Upper right quadrant; LL: Lower left quadrant; LR: Lower right quadrant). A, D: 
Control; B, E: TG treated; C, F: TG+GN; A, B, C: B220- FITC vs CD3- PE; D, E, F: GR1-FITC vs F4/80-PE. Graphical repre-
sentation of the effect of TG and GN on (II) CD45+B220+ and CD45+CD3+ cells, and (III) CD45+GR1+ and CD45+F4/80+ cells 
in the peripheral blood.   
Treatments 
B Cells (%) T Cells (%) Neutrophils (%) Macrophages (%) 
CD45+B220+ CD45+CD3+ CD45+GR1+ CD45+F4/80+ 
PB- Control 9.44 6.9 14.86 6.08 
PB- TG 0.33 13.16 10.89 21.52 
PB- TG+GN 8.34 7.34 3.64 2.98 
PF- Control 1.29 31.3 0.47 40.48 
PF- TG 0.98 43.26 0.45 60.45 
PF- TG+GN 4.22 22.97 1.25 2.63 
Table 9. Flow cytometry of CD45+ cells of peripheral blood of untreated mice and mice treated with TG and GN. PB and PF 
cells were stained with CD45- PerCP/Cy5.5, B220-FITC, CD3- PE, GR1- FITC and F4/80- PE. B220+ & GR1+ populations in 
PB decreased with TG and increased with GN (GR1+ decreased with GN), while CD3+ & F4/80+ populations increased with 
TG and decreased with GN.  The B220+ & GR1+ populations in PF decreased with TG and increased with GN, while CD3+ 
and F4/80+ populations increased with TG and decreased with GN. 
were 100%, 78.21% and 88.46%, respectively. With 
TG treatment, there was a 1.28 fold decrease in the 
proliferation as compared to control. Proliferation was 
restored to some extent (1.13 fold, with respect to TG- 
treated) by treatment with GN (Table 8 and Figure 
6E).  
 
Changes in B220, CD3, GR1and F4/80 population in 
peripheral blood and peritoneal fluid 
To assess the effect of GN on the infiltration of B 
cells, T cells, neutrophils and macrophages, flow cy-
tometry was done. CD3 has been used as a marker for 
T cells, while B220 has been used as a marker for B 
cells. Neutrophils are typically CD45+GR1+F4/80-, 
while macrophages are CD45+GR1-F4/80+. Inflamma-
tory monocytes are GR1+F4/80+.  
Peripheral Blood: As we see in Figure. 7, and Table 9, 
there was a larger population of B220+ cells (Figure 7-
I-A) and GR1+ cells (Figure 7-I-D) in the control as 
compared to TG (Figure 7-I-B and Figure 7-I-E) and 
TG+GN (Figure 7-I-C and Figure 7-I-F). However, 
while the population of B220+ has increased again in 
TG+GN, as compared to TG, the population of GR1+ 
has further reduced. The population of CD3+ cells 
(Figure 7-I-A) and F4/80+ cells (Figure 7-I-D) was 
much low in control than in TG- treated (Figure 7-I-B 
and Figure 7-I-E), which has again reduced in TG+GN 
(Figure 7-I-C, Figure 7-I-F, Figure 7-II and Figure 7-
III).    
Peritoneal Fluid: According to Figure. 8, and Table 9, 
there is a small population of B220+ cells (Figure 8-I-
A) and GR1+ cells (Figure 8-I-D) in the control, and a 
smaller population in TG (Figure 8-I-B and Figure 8-I-
E). There is a comparatively larger population in 
TG+GN (Figure 8-I-C and Figure 8-I-F). The popula-
tion of CD3+ cells (Figure 8-I-A) and F4/80+ cells 
(Figure 8-I-D) is lower in control than in TG-treated 
(Figure 8-I-B and Figure 8-I-E), which has again re-
duced in TG+GN (Figure 8-I-C, Figure 8-I-F, Figure 8
-II and Figure 8-III).    
In both cases, as expected, there was an increase in the 
population of F4/80+ macrophages with TG treatment. 
GN has reduced this population, both in the PB and in 
PF. There was also a large decrease in the population 
of the B220+ cells with TG, which has again been 
somewhat restored with GN. The CD3+ cell population 
has increased with TG and again decreased with GN in 
both PB and PF. However, while the population of 
GR1+ cells has decreased with TG in both PB and PF, 
it has further decreased with GN in the PB, but has 
increased in the PF.    
 
Discussion 
 
Nanoparticles show promising features for pharmaceu-
tical applications, especially for targeted drug delivery 
and bioimaging. The biomedical applications require a 
detailed understanding of interactions between 
nanoparticles and biological systems (Brandenberger 
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Figure 8. Flow cytometric analysis of peritoneal fluid done using BD FACSVerse. (I) 20,000 events were counted from gated 
CD45+ cells (UL: Upper left quadrant; UR: Upper right quadrant; LL: Lower left quadrant; LR: Lower right quadrant). A, D: 
Control; B, E: TG treated; C, F: TG+GN; A, B, C: B220- FITC vs CD3- PE; D, E, F: GR1-FITC vs F4/80-PE. Graphical repre-
sentation of the effect of TG and GN on (II) CD45+B220+ and CD45+CD3+ cells, and (III) CD45+GR1+ and CD45+F4/80+ cells 
in the peritoneal fluid.   
et al. 2010). Guar gum is a non-toxic and biodegrad-
able polymer with various applications such as emulsi-
fier, suspending and bioadhesive agent (Ahuja et al. 
2012). The guar gum nanoparticle (GN) used in this 
study was designed for a biomedical application. Upon 
exposure, nanoparticles interact with cells and enter 
into the cells by various mechanisms depending on 
their size, material, and surface characteristics. 
 In this study, we have performed both in vitro 
and in vivo experiments with guar gum nanoparticle to 
understand its therapeutic effect against inflammatory 
diseases. Cellular uptake was seen in adherent macro-
phage cells, where the unbound particles were washed 
off before microscopic observation to reduce their in-
terference in the microscopic studies. We performed 
MTS cell proliferation assay and nitric oxide assay to 
determine whether GN has any anti-inflammatory ef-
fect. Our experiments showed potential anti-
inflammatory and pro-regenerative activities of GN. 
As macrophages have special affinity for the carbohy-
drate-rich domains, due to the presence of C-type 
lectin receptors (mannose and galactose receptors) ex-
pressed on them (Kawasaki et al. 1986, McKenzie et 
al. 2007, Suzuki et al. 1996), we also performed recep-
tor inhibition studies using mannose and galactose to 
see whether the GN was taken up by the cells via these 
receptors. Free mannose and galactose were used as 
competitive inhibitors for the uptake of GN, with the 
idea that, the different concentrations of free mannose 
and galactose would inhibit the uptake of the galacto-
mannan nanoparticle by the macrophage cells through 
their receptors. The competitive binding of the free 
mannose and galactose to the nanoparticles with re-
spect to the mannose/ galactose-rich nanoparticles 
would reflect the specificity of the uptake of nanoparti-
cles in the cells. Our experiments, however, showed 
that the presence of exogenous mannose in the me-
dium led to greater inhibition of GN-uptake than the 
presence of galactose. Thus, it can be said that, the up-
take of GN was indeed occurring through the mannose 
receptors on the cells. The structural characterization 
of the mannosylated GN plays a significant role in the 
macrophage specific delivery of the nanoparticle. Dif-
ferent studies demonstrated that, engineered nanoparti-
cles could penetrate cell membranes and transport into 
cells of various types (Zhao et al. 2011). 
 One of the main concerns in the development 
of nanomedicines for disease diagnoses and therapy is 
to ensure that the designed nanoparticles can easily 
enter the cells. This is critical for the nanoparticles to 
be able to execute their diagnostic or therapeutic func-
tions in vivo. The processes leading to nanoparticles 
penetrating the cell membrane directly relate to their 
cellular uptake. Experimental results indicate that engi-
neered nanoparticles could penetrate cell membranes 
and transport into cells of various types, such as endo-
thelial cells, pulmonary epithelia, intestinal epithelia, 
alveolar macrophages, and neuron cells (Akerman et 
al. 2002, Florence et al. 2001, Hoet et al. 2001, Kato et 
al. 2003, Oberdorster et al. 2002). 
 As the GN uptake was observed in the macro-
phage cell line (RAW 264.7 cell) in vitro, we were 
interested to study its uptake by specific cell types 
among different cells. This was achieved by culturing 
primary cells obtained from murine peripheral blood, 
obtained from BALB/c mice. We used the CD45 
marker for screening hematopoietic cells among the 
mixed population of blood cells. Immunostaining GN-
treated cells with CD45-PerCP/Cy5.5 and counter-
staining with DAPI led to the observation that almost 
100% of the CD45+ cells had taken up the GN. This 
reflected that, GN uptake was not specific for a par-
ticular type of cells and it was non-specifically taken 
up by all hematopoietic lymphocytes.  
 Finally, we have performed an in vivo experi-
ment, in a murine model of thioglycollate- induced 
aseptic peritonitis. We treated mice (previously treated 
intraperitoneally with 3% thioglycollate to induce peri-
tonitis) intraperitoneally with 200 µg/ml GN. After 24 
hours, the mice were sacrificed, and peripheral blood 
(PB) and peritoneal fluid (PF) were collected. At the 
first stages of inflammation, the body tries to counter 
the inflammatory attack by its innate immune system. 
This increase in cells was assessed by the total cell 
(TC) count which indicates the development of inflam-
matory pathway. GN treatment successfully reduced 
the cellular infiltration in the PB and PF, compared the 
TC of TG- treated mice (Table 4, Figure 4A and 6A). 
CFU assay demonstrated that, GN successfully re-
stored the clonogenic potential of TG-induced diseased 
cells (Table 7 and Figure 6D), showing that the GN 
has helped the cells regain their potential to proliferate, 
which was also corroborated by the MTT assay (Table 
8 and Figure 6E). One of the main results of an inflam-
matory reaction in a body is the overproduction of pro-
oxidative agents, like nitric oxide (MacMicking et al. 
1997, Rahman 2007). In this work, in vivo nitric oxide 
assay also showed a significant decrease of NO con-
centration with GN treatment as compared to the NO 
concentration of the TG-induced diseased peritoneal 
fluid cells (Table 6 and Figure 6F). Flow cytometric 
analysis showed a marked reduction in the population 
of macrophages in both the PB (Table 9 and Figure 7) 
and the PF (Table 9 and Figure 8), with GN treatment. 
The results confirmed the effectiveness of guar 
gum nanoparticles against inflammatory disease. 
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Conclusion 
 
The increasing interest of the technology of drug form 
in natural biopolymers has become the reason for un-
dertaking investigations on the possibility of guar 
gum application. The in vitro studies performed with 
the RAW 264.7 cells showed successful uptake of the 
mannose rich guar gum nanoparticle in a short dura-
tion of time. In vivo experiment in a murine model of 
thioglycollate-induced aseptic peritonitis showed that, 
GN decreased the symptoms of the disease, including 
the total cell count, the differential count of neutrophils 
and monocytes, and the nitric oxide released by the 
cells. On the other hand, it has managed to increase the 
clonogenic potential of the cells as well as their prolif-
erative capacity. In the context of our current study, we 
can conclude that, GN can be used as an anti-
inflammatory agent against inflammatory diseases. 
Continued research in this topic will provide a better 
understanding of the therapeutic effect of guar gum 
nanoparticle and will undoubtedly help the design of 
safe and effective nanoparticle platforms for biomedi-
cal applications. 
 
Acknowledgements 
 
We wish to acknowledge Professor Arup Mukherjee, 
Department of Chemical Technology, University of 
Calcutta and his Research Fellow Mr. Sumanta Kumar 
Ghosh for preparing Guar gum nanoparticles and pro-
viding us with it. We wish to acknowledge the Indian 
Council for Medical Research (ICMR), New Delhi, for 
providing a fellowship to NG & SB, and the Univer-
sity Grants Commission (UCG), New Delhi, for pro-
viding fellowship and contingency grant to SM. We 
also wish to acknowledge UGC-SAP, UPE-Phase II 
and DST-FIST for providing departmental infrastruc-
ture. We acknowledge the Indian Institute of Chemical 
Biology (IICB), Kolkata, for allowing us the use of the 
Andor Spinning Disk Confocal Microscope. We also 
acknowledge the BD- CoE at the Centre for Research 
in Nanoscience & Nanotechnology (CRNN), Univer-
sity of Calcutta, Kolkata, for allowing us to use the BD 
FACSVerse. This work was funded from the corre-
sponding author’s grant with the Indian Council of 
Medical Research (ICMR), New Delhi.  
 
Conflicts of interest 
 
The authors declare no conflicts of interest. 
 
 
 
Author contributions 
 
NG and SM performed the experiments, analysed the 
data and wrote the manuscript. SB gave valuable input 
to the manuscript. ERB initiated the project with her 
idea, designed the experiments, analyzed all data and 
wrote the manuscript. 
 
References 
 
Ahuja M, Kumar A & Singh K 2012 Synthesis, char-
acterization and in vitro release behavior of carboxy-
methyl xanthan. Int J Bio. Macromol 51 1086-1090 
Akerman ME, Chan WC, Laakkonen P, Bhatia SN & 
Ruoslahti E 2002 Nanocrystal targeting in vivo. Proc 
Nat. Acad Sci USA 99 12617-12621 
Brandenberger C, Mühlfeld C, Ali Z, Lenz AG, 
Schmid O, Parak WJ, Gehr P & Rothen-Rutishauser B 
2010 Quantitative evaluation of cellular uptake and 
trafficking of plain and polyethylene glycol-coated 
gold nanoparticles. Small 6 1669-1678 
Florence AT & Hussain N 2001 Transcytosis of 
nanoparticle and dendrimer delivery systems: evolving 
vistas. Adv Drug Deliv Rev 50 S69-89 
Ghosh SK, Abdullah F & Mukherjee A 2015 Fabrica-
tion and fluorescent labeling of guar gum nanoparticles 
in a surfactant free aqueous environment. Mater Sci 
Eng C Mater Biol Appl 46 521-529 
Hartemink R, Schoustra SE & Rombouts FM 1999 
Degradation of Guar Gum by intestinal bacteria. Biosci 
Microfl 18 17-25 
Higashi N, Fujioka K, Denda-Nagai K, Hashimoto S, 
Nagai S, Sato T, Fujita Y, Morikawa A, Tsuiji M, Mi-
yata-Takeuchi M, Sano Y, Suzuki N, Yamamoto K, 
Matsushima K & Irimura T 2002 The macrophage C-
type  lec t in  spec i f ic  for  ga lac tose /N -
acetylgalactosamine is an endocytic receptor expressed 
on monocyte-derived immature dendritic cells. J Biol 
Chem 277 20686-20693 
Hoet PH & Nemery B 2001 Stimulation of phagocyto-
sis by ultrafine particles. Toxicol Appl Pharmacol 176 
203 
Honery S & Zahir F 2013 Effect of zeta potential on 
the properties of Nano drug delivery systems- a re-
view. Trop J Pharm Res 12 255-264 
Kato T, Yashiro T, Murata Y, Herbert DC, Oshikawa 
K, Bando M, Ohno S & Sugiyama Y 2003 Evidence 
that exogenous substances can be phagocytized by al-
veolar epithelial cells and transported into blood capil-
laries. Cell Tissue Res 311 47-51 
Kawasaki T, Ii M, Kozutsumi Y & Yamashina I 1986 
Isolation and characterization of a receptor lectin spe-
cific for galactose/N-acetylgalactosamine from macro-
phages. Carbohydr Res 151 197-206 
Journal of Molecular Biochemistry, 2018   26 
Lam D, Harris D & Qin Z 2013 Inflammatory Media-
tor Profiling Reveals Immune Properties of Chemotac-
tic Gradients and Macrophage Mediator Production 
Inhibition during Thioglycollate Elicited Peritoneal 
Inflammation. Med Inflam 2013 931562  
Leteux C, Chai W, Loveless RW, Yuen CT, Uhlin-
Hansen L, Combarnous Y, Jankovic M, Maric SC, 
Misulovin Z, Nussenzweig MC & Feizi T 2000 The 
cysteine-rich domain of the macrophage mannose re-
ceptor is a multispecific lectin that recognizes chon-
droitin sulfates A and B and sulfated oligosaccharides 
of blood group Lewis (a) and Lewis (x) types in addi-
tion to the sulfated N-glycans of lutropin. J Exp Med 
191 1117-1126 
Liu Y, Chirino AJ, Misulovin Z, Leteux C, Feizi T, 
Nussenzweig MC & Bjorkman PJ 2000 Crystal struc-
ture of the cysteine-rich domain of mannose receptor 
complexed with a sulfated carbohydrate ligand. J Exp 
Med 191 1105-1116 
MacMicking J, Xie QW & Nathan C 1997 Nitric oxide 
and macrophage function. Annu Rev Immunol 15 323-
350 
McKenzie EJ, Taylor PR, Stillion RJ, Lucas AD, Har-
ris J, Gordon S & Martinez-Pomares L 2007 Mannose 
Receptor Expression and Function Define a New 
Population of Murine Dendritic Cells. J Immunol 178 
4975-4983 
Mitra S, Biswas S, Sinha A, Jana NR & Banerjee ER 
2015 Therapeutic use of Fisetin and Fisetin Loaded on 
Mesoporous Carbon Nanoparticle (MCN) in Thiogly-
collate-induced Peritonitis. J Nanomed Nanotechnol 6 
332 
Oberdorster G, Sharp Z, Atudorei V, Elder A, Gelein 
R, Lunts A, Kreyling W & Cox C 2002 Extrapulmon-
ary translocation of ultrafine carbon particles following 
whole-body inhalation exposure of rats. J Toxicol En-
viron Health A 65 1531-1543 
Rahman K 2007 Studies on free radicals, antioxidants, 
and co-factors. Clin Interv Aging 2 219-236 
Sahoo R, Jacob PJS & Sahoo S 2013 Biomedical ap-
plications of green biopolymer guar gum. J Pharm 
Biomed Sci 35 1783-1787 
Saikh T & Kumar SS 2011 Pharmaceutical and phar-
macological profile of guar gum an overview. Int J 
Pharm Pharm Sci 3 38-40 
Suzuki N, Yamamoto K, Toyoshima S, Osawa T & 
Irimura T 1996 Molecular cloning and expression of 
cDNA encoding human macrophage C-type lectin. Its 
unique carbohydrate binding specificity for Tn antigen. 
J Immunol 156 128-135 
Zhang X, Goncalves R & Mosser DM 2008 The isola-
tion and characterization of murine macrophages. Curr 
Protoc Immunol 14 14.1 
Zhao F, Zhao Y, Liu Y, Chang X, Chen C & Zhao Y 
2011 Cellular uptake, intracellular trafficking, 
and cytotoxicity of nanomaterials. Small 7 1322-1337 
 
27   Journal of Molecular Biochemistry, 2018    
